Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

We present a phase 2, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL-2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Main Authors: Konopleva, Marina, Pollyea, Daniel A., Potluri, Jalaja, Chyla, Brenda, Hogdal, Leah, Busman, Todd, McKeegan, Evelyn, Salem, Ahmed Hamed, Zhu, Ming, Ricker, Justin L., Blum, William, DiNardo, Courtney D., Kadia, Tapan, Dunbar, Martin, Kirby, Rachel, Falotico, Nancy, Leverson, Joel, Humerickhouse, Rod, Mabry, Mack, Stone, Richard, Kantarjian, Hagop, Letai, Anthony
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5436271/
https://ncbi.nlm.nih.gov/pubmed/27520294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0313
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares